Barriers to treatment access for Chagas disease in Mexico.
According to World Health Organization (WHO) prevalence estimates, 1.1 million people in Mexico are infected with Trypanosoma cruzi, the etiologic agent of Chagas disease (CD). However, limited information is available about access to antitrypanosomal treatment. This study assesses the extent of acc...
Main Authors: | Jennifer M Manne, Callae S Snively, Janine M Ramsey, Marco Ocampo Salgado, Till Bärnighausen, Michael R Reich |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS Neglected Tropical Diseases |
Online Access: | http://europepmc.org/articles/PMC3798390?pdf=render |
Similar Items
-
Access to Chagas disease treatment in the United States after the regulatory approval of benznidazole.
by: Kota Yoshioka, et al.
Published: (2020-06-01) -
Opportunity cost for early treatment of Chagas disease in Mexico.
by: Janine M Ramsey, et al.
Published: (2014-04-01) -
Community resilience and Chagas disease in a rural region of Mexico
by: José Antonio Santana Rangel, et al.
Published: (2016-01-01) -
Barriers to Diagnosis Access for Chagas Disease in Colombia
by: Mario Javier Olivera, et al.
Published: (2018-01-01) -
Ecologic Niche Modeling and Potential Reservoirs for Chagas Disease, Mexico.
by: A. Townsend Peterson, et al.
Published: (2002-07-01)